Article
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2017
Paz-Ares L, Tan E-H, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang J C-H, Mok T, Lee K H, Lu S, Shi Y, Lee D H, Laskin J, Kim D-W, Laurie S A, Kölbeck K, Fan J, Dodd N, Märten A, Park K
Abstract excerpt
Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data. Patients and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.